220619-73-8
220619-73-8 用途与合成方法
|
RXRα 0.4 nM (Kd) |
RXRβ 3.6 nM (Kd) |
RXRγ 3.8 nM (Kd) |
RXRα 0.2 nM (EC 50 ) |
RXRβ 0.8 nM (EC 50 ) |
RXRγ 0.08 nM (EC 50 ) |
AGN194204 (NRX194204; 0-100 nM; 24 hours; E, RAW cells) treatment blocks the ability of lipopolysaccharide and tumor necrosis factor-α to induce the release of nitric oxide and interleukin 6 and the degradation of IKBα in RAW264.7 macrophage-like cells.
AGN194204 (NRX194204; 1 μM; 72 hours; SK-BR-3 human breast cancer cells) treatment induces apoptosis in breast cancer cells.
Apoptosis Analysis
| Cell Line: | SK-BR-3 human breast cancer cells |
| Concentration: | 1 μM |
| Incubation Time: | 72 hours |
| Result: | Induced apoptosis in lung and breast cancer cells. |
Western Blot Analysis
| Cell Line: | E, RAW cells |
| Concentration: | 0 nM, 1 nM, 10 nM and 100 nM |
| Incubation Time: | 24 hours |
| Result: | Blocked the ability of lipopolysaccharide and tumor necrosis factor-α to induce the release of nitric oxide and interleukin 6 and the degradation of IKBα in RAW264.7 macrophage-like cells. |
AGN194204 (NRX194204; 30-60 mg/kg; oral administration; daily; for 15 weeks; female A/J mice) treatment significantly reduces the number and size of tumors on the surface of the lungs and reduces the total tumor volume per slide by 64% to 81% compared with the control group.
| Animal Model: | Female A/J mice with vinyl carbamate |
| Dosage: | 30 mg/kg, 60 mg/kg |
| Administration: | Oral administration; daily; for 15 weeks |
| Result: | Significantly reduced the number and size of tumors on the surface of the lungs and reduced the total tumor volume per slide by 64% to 81% compared with the control group. |
